Dapagliflozin for treating chronic kidney disease

  • Technology appraisal guidance
  • TA775
  • Published: 
Download guidance (PDF)

2 Information about dapagliflozin

Marketing authorisation indication

2.1 Dapagliflozin (Forxiga, AstraZeneca) is indicated for 'treating chronic kidney disease (CKD) in adults'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for dapagliflozin.

Price

2.3 The list price of dapagliflozin is £36.59 for a 28‑pack of 10 mg tablets, giving a yearly cost of £477.30. Costs may vary in different settings because of negotiated procurement discounts.